Eisai Q1 revenue up 7% driven by Alzheimer's drug

Eisai reported consolidated revenue of 202.7bn yen for Q1 FY2025, up 7.2% year-on-year, with operating profit jumping 54.7% to 20.7bn yen.

Growth was primarily driven by Alzheimer's drug Leqembi and insomnia treatment Dayvigo. Leqembi revenue surged to 23.1bn yen, up 369.3% year-on-year, with significant growth across Japan, Americas and China.

Pharmaceutical business revenue increased 6.4% to 198.4bn yen, while total assets rose to 1.41 trillion yen reflecting increased inventories for Leqembi production.